{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:12:51Z","timestamp":1793236371002,"version":"4.5.0"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Otolaryngol Head Neck Surg"],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"\n Importance<\/jats:title>\n Radioactive iodine treatment for differentiated thyroid cancer has been associated with second primary malignant neoplasms, but age-specific risks remain poorly understood.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the association of age with increased risk of second primary malignant neoplasm after radioactive iodine treatment for differentiated thyroid cancer (DTC).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective cohort study used data from 8 cancer registries in the US National Cancer Institute\u2019s Surveillance, Epidemiology, and End Results Program for 1975 to 2021. Patients who received radioactive iodine treatment for DTC were identified; those with fewer than 2 years of follow-up, missing follow-up data, or distant metastases at diagnosis were excluded. Included patients were categorized into 3 age groups: 15 to 44, 45 to 64, and 65 years or older. Among 5-year survivors, median (IQR) follow-up time was 14.7 (8.6-24.0) years in the 15- to 44-year age group; 8.3 (6.4-11.4) years in the 45- to 64-year group; and 9.3 (6.9-12.7) years in the 65 years or older group. Data were analyzed from May to July 2024.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Radioactive iodine vs no radioactive iodine.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Relative risks (RR) and 95% CIs for solid and hematologic second primary malignant neoplasms, calculated using multivariable Poisson regression models adjusted for age, sex, and latency.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The study sample comprised 72 412 patients with nonmetastatic DTC, of whom 28\u202f432 (39%) were age 15 to 44 years; 34\u202f009 (47%), age 45 to 64 years; and 9971 (14%), 65 years or older. In the 15- to 44-year age group, radioactive iodine was associated with an increased risk of hematologic cancers (RR,\u20091.35; 95% CI, 1.02-1.80), specifically myeloma (RR,\u20094.22; 95% CI, 1.68-10.62). In the 45- to 64-year age group, the analyses showed increased risks of prostate cancer (RR,\u20091.61; 95% CI, 1.10-2.37), salivary gland cancer (RR, 10.22; 95% CI, 1.27-82.24), and nodal non-Hodgkin lymphoma (RR, 2.81; 95% CI, 1.34-5.89). The overall risk of a solid second primary malignant neoplasm was not elevated (RR, 0.94; 95% CI, 0.76-1.16), but hematologic second primary malignant neoplasm risk was elevated (RR,\u20091.73; 95% CI, 1.14-2.60). Patients in the group that was 65 years and older showed elevated risks of stomach (RR,\u20094.06; 95% CI, 1.05-15.81), esophagus (RR,\u200911.42; 95% CI, 1.40-93.3), nonepithelial skin cancers (RR, 10.52; 95% CI, 1.09-88.77), and acute myeloid leukemia (RR, 3.26; 95% CI, 1.15-9.24). The overall risk of a solid second primary malignant neoplasm was elevated (RR, 1.88; 95% CI, 1.59-2.21), whereas risk of hematologic malignant neoplasm was not (RR, 1.35; 95% CI, 0.97-1.87).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This cohort study found that the risk of radioactive iodine\u2212associated second primary malignant neoplasm among patients who received radioactive iodine for DTC varies significantly by age group, with distinct patterns in middle-aged compared with older adults. These findings suggest a need for age-specific surveillance strategies in radioactive iodine\u2212treated DTC survivors. Further research is needed to establish optimal screening protocols.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoto.2025.2626","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T15:00:31Z","timestamp":1755788431000},"page":"947","source":"Crossref","is-referenced-by-count":5,"title":["Age-Specific Risk of Second Primary Malignant Neoplasm After Radioactive Iodine Treatment for Differentiated Thyroid Cancer"],"prefix":"10.1001","volume":"151","author":[{"given":"Julia J.","family":"An","sequence":"first","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Choi","sequence":"additional","affiliation":[{"name":"Independent Researcher, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"Institute for Health Care Delivery Science, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marita S.","family":"Teng","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike","family":"van Gerwen","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"23","key":"ooi250051r2","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMra1501993","article-title":"Biologic and clinical perspectives on thyroid cancer.","volume":"375","author":"Fagin","year":"2016","journal-title":"N Engl J Med"},{"issue":"10061","key":"ooi250051r3","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1016\/S0140-6736(16)30172-6","article-title":"Thyroid cancer.","volume":"388","author":"Cabanillas","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"ooi250051r4","doi-asserted-by":"publisher","first-page":"260","DOI":"10.5603\/EP.a2023.0028","article-title":"Hazard ratios of second primary malignancy after radioiodine for differentiated thyroid carcinoma: a large-cohort retrospective study.","volume":"74","author":"Wu","year":"2023","journal-title":"Endokrynol Pol"},{"issue":"8","key":"ooi250051r5","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1097\/MNM.0000000000000132","article-title":"Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma.","volume":"35","author":"Fard-Esfahani","year":"2014","journal-title":"Nucl Med Commun"},{"issue":"11","key":"ooi250051r6","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.6004\/jnccn.2010.0094","article-title":"Complications of radioactive iodine treatment of thyroid carcinoma.","volume":"8","author":"Lee","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"ooi250051r7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/cen.12581","article-title":"The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq.","volume":"83","author":"Khang","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"18","key":"ooi250051r8","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1200\/JCO.2017.75.0232","article-title":"Risk of hematologic malignancies after radioiodine treatment of well-differentiated thyroid cancer.","volume":"36","author":"Molenaar","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"ooi250051r9","doi-asserted-by":"publisher","first-page":"e2580","DOI":"10.1210\/clinem\/dgab192","article-title":"Radioactive iodine treatment for children and young adults with thyroid cancer in South Korea: a population-based study.","volume":"106","author":"Seo","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"ooi250051r10","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv314","article-title":"Use of radioactive iodine for thyroid cancer and risk of second primary malignancy: a nationwide population-based study.","volume":"108","author":"Teng","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"ooi250051r11","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1089\/thy.2018.0244","article-title":"A systematic review and meta-analysis of subsequent malignant neoplasm risk after radioactive iodine treatment of thyroid cancer.","volume":"28","author":"Yu","year":"2018","journal-title":"Thyroid"},{"issue":"2","key":"ooi250051r12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/MNM.0000000000000419","article-title":"Risk of second primary breast cancer after radioactive iodine treatment in thyroid cancer: a systematic review and meta-analysis.","volume":"37","author":"Zhang","year":"2016","journal-title":"Nucl Med Commun"},{"issue":"13","key":"ooi250051r14","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1200\/JCO.21.01841","article-title":"Association between radioactive iodine treatment for pediatric and young adulthood differentiated thyroid cancer and risk of second primary malignancies.","volume":"40","author":"Pasqual","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"ooi250051r16","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1093\/aje\/kwg278","article-title":"A methodological issue in the analysis of second-primary cancer incidence in long-term survivors of childhood cancers.","volume":"158","author":"Yasui","year":"2003","journal-title":"Am J Epidemiol"},{"issue":"2","key":"ooi250051r17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1089\/thy.2016.0266","article-title":"Estimation of second primary cancer risk after treatment with radioactive iodine for differentiated thyroid carcinoma.","volume":"27","author":"Corr\u00eaa","year":"2017","journal-title":"Thyroid"},{"issue":"22","key":"ooi250051r18","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1056\/NEJMra072149","article-title":"Computed tomography\u2013an increasing source of radiation exposure.","volume":"357","author":"Brenner","year":"2007","journal-title":"N Engl J Med"},{"issue":"8","key":"ooi250051r19","first-page":"584","article-title":"Excess lifetime cancer mortality risk attributable to radiation exposure from computed tomography examinations in children.","volume":"9","author":"Chodick","year":"2007","journal-title":"Isr Med Assoc J"},{"issue":"2","key":"ooi250051r20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/0146645314558019","article-title":"Radiation dose to patients from radiopharmaceuticals: a compendium of current information related to frequently used substances.","volume":"44","author":"Mattsson","year":"2015","journal-title":"Ann ICRP"},{"issue":"9","key":"ooi250051r21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.34841","article-title":"Development of melanoma and other nonkeratinocyte skin cancers after thyroid cancer radiation.","volume":"7","author":"Rezaei","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"16","key":"ooi250051r22","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.3390\/cancers15164146","article-title":"RET-altered cancers-a tumor-agnostic review of biology, diagnosis and targeted therapy activity.","volume":"15","author":"Desilets","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5","key":"ooi250051r23","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41574-021-00470-9","article-title":"The importance of the RET gene in thyroid cancer and therapeutic implications.","volume":"17","author":"Salvatore","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"ooi250051r24","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1089\/thy.2023.0529","article-title":"CHEK2 founder variants and thyroid cancer risk.","volume":"34","author":"Brock","year":"2024","journal-title":"Thyroid"},{"key":"ooi250051r25","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/294575","article-title":"CHEK2 (*) 1100delC mutation and risk of prostate cancer.","volume":"2014","author":"Hale","year":"2014","journal-title":"Prostate Cancer"},{"issue":"6","key":"ooi250051r26","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1089\/thy.2015.0067","article-title":"Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer.","volume":"25","author":"Marti","year":"2015","journal-title":"Thyroid"},{"issue":"19","key":"ooi250051r27","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1002\/cncr.26070","article-title":"Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.","volume":"117","author":"Iyer","year":"2011","journal-title":"Cancer"},{"issue":"1","key":"ooi250051r28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1210\/er.2001-0029","article-title":"The sodium\/iodide Symporter (NIS): characterization, regulation, and medical significance.","volume":"24","author":"Doh\u00e1n","year":"2003","journal-title":"Endocr Rev"},{"issue":"4","key":"ooi250051r29","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6498\/abbe37","article-title":"Ionising radiation as a risk factor for lymphoma: a review.","volume":"40","author":"Harbron","year":"2020","journal-title":"J Radiol Prot"},{"issue":"3","key":"ooi250051r30","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1667\/RR2892.1","article-title":"The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950-2001.","volume":"179","author":"Hsu","year":"2013","journal-title":"Radiat Res"},{"issue":"8","key":"ooi250051r32","doi-asserted-by":"publisher","first-page":"e346","DOI":"10.1016\/S2352-3026(18)30092-9","article-title":"Leukaemia and myeloid malignancy among people exposed to low doses (<100 mSv) of ionising radiation during childhood: a pooled analysis of nine historical cohort studies.","volume":"5","author":"Little","year":"2018","journal-title":"Lancet Haematol"},{"issue":"12","key":"ooi250051r33","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1038\/s41375-018-0149-2","article-title":"Risk of subsequent myeloid neoplasms after radiotherapy treatment for a solid cancer among adults in the United States, 2000-2014.","volume":"32","author":"Teepen","year":"2018","journal-title":"Leukemia"},{"issue":"10","key":"ooi250051r34","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.3390\/cancers14102505","article-title":"Radioactive iodine treatment for thyroid cancer patients increases the risk of long-term gastrointestinal disorders: a nationwide population-based cohort analysis.","volume":"14","author":"Lee","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"ooi250051r35","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1007\/BF03345302","article-title":"Sodium iodide symporter expression and radioiodine distribution in extrathyroidal tissues.","volume":"27","author":"Bruno","year":"2004","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"ooi250051r36","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1089\/108497803322285206","article-title":"Biokinetics of iodide in man: refinement of current ICRP dosimetry models.","volume":"18","author":"Johansson","year":"2003","journal-title":"Cancer Biother Radiopharm"},{"issue":"17","key":"ooi250051r37","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.3390\/cancers16173096","article-title":"Decision variables for the use of radioactive iodine in patients with thyroid cancer at intermediate risk of recurrence.","volume":"16","author":"Newman","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"7","key":"ooi250051r38","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1089\/thy.2013.0045","article-title":"The increasing incidence of thyroid cancer: the influence of access to care.","volume":"23","author":"Morris","year":"2013","journal-title":"Thyroid"},{"issue":"3","key":"ooi250051r39","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.beem.2017.04.010","article-title":"Radioactive iodine (RAI) therapy for metastatic differentiated thyroid cancer.","volume":"31","author":"Verburg","year":"2017","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"10","key":"ooi250051r40","doi-asserted-by":"publisher","first-page":"T125","DOI":"10.1530\/ERC-21-0161","article-title":"Tailoring the approach to radioactive iodine treatment in thyroid cancer.","volume":"28","author":"Mayson","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"ooi250051r41","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1089\/thy.2012.0380","article-title":"Factors that influence radioactive iodine use for thyroid cancer.","volume":"23","author":"Papaleontiou","year":"2013","journal-title":"Thyroid"},{"key":"ooi250051r1","unstructured":"Cancer Stat Facts. Thyroid Cancer. Accessed November 6th, 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/thyro.html"},{"key":"ooi250051r13","unstructured":"US National Research Council of the National Academies. Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2. 2006. Accessed July 21, 2025. https:\/\/nap.nationalacademies.org\/catalog\/11340\/health-risks-from-exposure-to-low-levels-of-ionizing-radiation"},{"key":"ooi250051r15","unstructured":"Berrington de Gonz\u00e1lez? A BA, Rajaraman? P, Schubauer-Berigan? M, Thun? M, Linet? MS, Cerhan? JR, et al. Cancer epidemiology and prevention, 4th edition. Accessed July 21, 2025. https:\/\/www.scribd.com\/document\/384238857\/Cancer-Epidemiology-and-Prevention-4th-Edition"},{"key":"ooi250051r31","unstructured":"US Centers for Disease Control and Prevention. 2025 US Cancer Statistics. https:\/\/www.cdc.gov\/united-states-cancer-statistics\/publications\/uscs-highlights.html"}],"container-title":["JAMA Otolaryngology\u2013Head & Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/articlepdf\/2838008\/jamaotolaryngology_an_2025_oi_250051_1759347475.55829.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T15:00:55Z","timestamp":1760022055000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/fullarticle\/2838008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoto.2025.2626","relation":{},"ISSN":["2168-6181"],"issn-type":[{"value":"2168-6181","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}